title: Critical review of cancer risk associated with angiotensin receptor blocker therapy.
abstract: The role of drugs in new cancer occurrence and cancer-related death is a major concern. Recently, a meta-analysis raised the possibility that angiotensin receptor blockers (ARBs) might have an adverse effect on patients. This generated a significant debate until the publication of two further meta-analyses, neither of which demonstrated an increased risk of new cancer occurrence or cancer-related death with the use of ARBs in patients with hypertension, heart failure, and/or nephropathy. This illustrates that the results of meta-analyses should be interpreted cautiously and critically as bias, such as selection bias, might lead to erroneous conclusions. Overall, the bulk of evidence today indicates that ARBs are not associated with increased cancer risk.
authors.affiliation: Service of Nephrology and Hypertension Consultation, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
authors.forename: Grégoire
authors.initials: G
authors.lastname: Wuerzner
authors.forename: Michel
authors.initials: M
authors.lastname: Burnier
authors.forename: Bernard
authors.initials: B
authors.lastname: Waeber
mesh_terms: D000804:Angiotensin II / Q000502:physiology; D057911:Angiotensin Receptor Antagonists / Q000009:adverse effects* / Q000494:pharmacology; D002986:Clinical Trials as Topic; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D015201:Meta-Analysis as Topic; D009369:Neoplasms / Q000139:chemically induced*; D009389:Neovascularization, Pathologic; D009765:Obesity / Q000150:complications; D011945:Receptors, Angiotensin / Q000502:physiology; D012307:Risk Factors
chemical_list: D057911:Angiotensin Receptor Antagonists; D011945:Receptors, Angiotensin; D000804:Angiotensin II